Summary
Signal counts
Assets tracked: 13
Watchlist assets: 10
Registry stop assets: 0
Sponsor overview
Fudan University
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT05749588 | https://clinicaltrials.gov/study/NCT07150208 | https://clinicaltrials.gov/study/NCT04299581 | https://clinicaltrials.gov/study/NCT04720131 | https://clinicaltrials.gov/study/NCT07419880 | https://clinicaltrials.gov/study/NCT06551051 | https://clinicaltrials.gov/study/NCT06041724 | https://clinicaltrials.gov/study/NCT05575804 | https://clinicaltrials.gov/study/NCT06793332 | https://clinicaltrials.gov/study/NCT05594095 | https://clinicaltrials.gov/study/NCT07509515 | https://clinicaltrials.gov/study/NCT07368543 | https://clinicaltrials.gov/study/NCT06718933 | https://clinicaltrials.gov/study/NCT06649331 | https://clinicaltrials.gov/study/NCT05824325 | https://clinicaltrials.gov/study/NCT07317778 | https://clinicaltrials.gov/study/NCT07307287 | https://clinicaltrials.gov/study/NCT05468138
Assets
Linked programs
- A1: SHR-A1811: Watchlist Signal (2/5)
- Bevacizumab (Bev): Low Signal (1/5)
- Camrelizumab: Timeline Staleness Signal (4/5)
- Cromolyn, TQB2102, and Panpulimab: Low Signal (1/5)
- duloxetine: Timeline Staleness Signal (4/5)
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy: Watchlist Signal (3/5)
- GQ1001+pyrotinib: Timeline Staleness Signal (4/5)
- Ivonescimab Combined With TROP2 ADC: Watchlist Signal (2/5)
- PIK3CA inhibitor: Timeline Staleness Signal (4/5)
- QLC5513: Low Signal (0/5)
- Sacituzumab Govitecan: Operational Burden Signal (2/5)
- SHR-A1811: Timeline Staleness Signal (4/5)
- SOX: Timeline Staleness Signal (4/5)